하이드로겔 드레싱 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the hydrogel dressing market size is expected to increase from USD 0.89 billion in 2025 to USD 0.95 billion in 2026 and reach USD 1.27 billion by 2031, growing at a CAGR of 5.98% over 2026-2031.

This report is Segmented by Product Type (Amorphous Hydrogel Dressings, Impregnated Hydrogel Dressings, and Sheet Hydrogel Dressings), Raw Material (Synthetic Hydrogels, Natural Hydrogels, and Semi-Synthetic Hydrogels), Application (Chronic Wounds and Acute Wounds), End User (Hospitals, Home Healthcare, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Hydrogel Dressing Market Trends and Insights

Rising Prevalence of Chronic Wounds

Diabetic foot ulcers, pressure ulcers, and venous leg ulcers now affect more than 40 million people worldwide, and United States treatment costs exceed USD 50 billion annually. The International Working Group on the Diabetic Foot noted in 2024 that 1-year mortality after a diabetic foot ulcer diagnosis matches some cancers. Yet, fewer than half of high-risk patients receive moisture-balanced dressings. Hydrogels maintain moist environments that accelerate autolytic debridement and lower nursing frequency from daily changes to three-day intervals. Skilled-nursing facilities experience labor reductions when hydrogel replaces gauze, supporting its adoption in capitated payment systems. These factors collectively raise baseline demand in the hydrogel dressing market

Shift from Gauze to Evidence-Based Advanced Dressings

Guidelines from NICE and the Wound Healing Society emphasize moist healing and faster epithelialization, but cost sensitivity slows uptake in some hospitals. Bundled payments fold dressing costs into procedure codes, prompting procurement to favor options that shorten stays and cut readmissions. Hydrogels prove particularly valuable in low-to-moderate exudate wounds, though high-exudate ulcers still require absorbent foams. These reimbursement shifts add momentum to the hydrogel dressing market across developed regions.

High Unit and Manufacturing Cost Versus Conventional Dressings

Hydrogels retail at USD 3-15 per unit, far above the USD 0.10-0.50 for gauze, causing sticker shock in low-income settings. Specialty polymers like medical-grade hyaluronic acid cost up to USD 500 per kilogram, making materials the most significant expense driver. Sterile packaging adds another USD 0.50-2.00 per unit, and these costs compound across high-volume chronic-wound regimens. A 2024 Journal of Wound Care study still showed an 18% lower total episode cost than gauze, because fewer changes and infections offset the material premium. Yet price remains a barrier in India and Southeast Asia, limiting penetration of the hydrogel dressing market outside urban hospitals.

Other drivers and restraints analyzed in the detailed report include:

1. Innovation in Antimicrobial & Stimuli-Responsive Hydrogels
2. Growing Surgical & Burn Caseloads
3. Limited Absorption for Heavy-Exudate Wounds

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Amorphous formulations held 64.55% of the hydrogel dressing market share in 2025, reflecting their ability to fill irregular cavities and tunnel wounds. Sheet variants, however, are growing at 8.25% CAGR because burn units prefer pre-formed pads that cool tissue and reduce nursing time. Amorphous gels require secondary retention, which increases labor, but they permit clinicians to pack undermined tissue with precise moisture control. Sheet hydrogels deliver a uniform thickness and adhere gently, reducing dressing changes by up to 2 per week and improving patient comfort.

Regulatory compliance is strict across formats: ISO 10993 testing adds up to USD 100,000 per formulation. The FDA cleared a sheep-collagen sheet hydrogel in 2025, confirming that novel biomaterials can pass through the 510(k) pathway when equivalence is demonstrated. Sheet hydrogels face competition from silicone foams with better exudate handling, yet remain favored where autolytic debridement is required, keeping both formats integral to the hydrogel dressing market.

Synthetic polymers accounted for 60.53% of the hydrogel dressing market in 2025, as polyethylene glycol and polyacrylamide offer reproducible mechanical properties and sterilization compatibility. Hybrid blends of synthetic backbones with bioactive chitosan or hyaluronic acid are advancing at an 8.85% CAGR. Natural components improve cell signaling and growth-factor retention, leading to faster healing in early studies. Batch variability and higher costs still constrain pure natural gels, yet hybrids mitigate these issues by keeping synthetic durability.

Supply-chain risks shape strategy. China's dominance in hyaluronic acid exposes producers to geopolitical swings, prompting multisource procurement. ISO 13485 audits add overhead yet prevent recalls from contaminated lots. The resulting emphasis on resilience and bioactivity will likely expand hybrid revenue share within the hydrogel dressing market.

Complete Report Scope:

• By Product Type
  • Amorphous Hydrogel Dressings
  • Impregnated Hydrogel Dressings
  • Sheet Hydrogel Dressings
• By Raw Material
  • Synthetic Hydrogels
  • Natural Hydrogels
  • Semi-synthetic / Hybrid Hydrogels
• By Application
  • Chronic Wounds
    • Diabetic Foot Ulcers
    • Pressure Ulcers
    • Venous Leg Ulcers
  • Acute Wounds
    • Burns
    • Surgical & Traumatic Wounds
• By End User
  • Hospitals
  • Home Healthcare
  • Ambulatory Surgical Centers
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 40.13% of the hydrogel dressing market in 2025, driven by robust reimbursement and early smart-dressing pilots. Medicare codes still cover hydrogels, yet bundled payments pass cost pressure to providers, prompting data-backed purchasing. Canada's provincial formularies vary; Ontario funds hydrogels in home care, whereas Alberta requires prior authorization, creating uneven uptake. Mexico benefits from medical tourism and expanding social-insurance coverage, boosting imports from United States suppliers.

Europe remains sizable but governed by strict Medical Device Regulation 2017/745 processes. Germany reimburses listed dressings through the Hilfsmittelverzeichnis, while unlisted products need case approvals. The United Kingdom purchases centrally through NHS Supply Chain, and NICE's 2024 review found insufficient evidence to prefer hydrogels, which has slowed adoption. France's LPPR process can take up to 18 months, delaying full reimbursement. Southern Europe shows slower uptake due to tighter budgets.

Asia-Pacific posts the highest CAGR of 9.51%, driven by China, India, Japan, Australia, and South Korea. China reduced Class II approval timelines to about 12-15 months, letting domestic leaders such as Winner Medical raise exports 12.6% year-on-year. India's Class B registration system welcomes multinationals without mandated clinical trials, while Japan's PMDA allows Class II notifications through a Marketing Authorization Holder structure. Australia's high per-capita wound-care spend and South Korea's accelerating approvals make both countries attractive launch pads for premium offerings, reinforcing the hydrogel dressing market's pivot eastward.

Gulf states import premium dressings for private hospitals serving medical tourists, yet public tenders remain gauze-heavy. South Africa's dual public-private system creates a split market, while Brazil's ANVISA fast-tracks low-risk devices yet budget constraints limit nationwide roll-out. Currency volatility in Argentina and price controls elsewhere keep penetration uneven, but rising diabetes rates still add incremental volumes to the hydrogel dressing market.

1. Advanced Medical Solutions Group
2. Alliqua BioMedical / NEXGEL Inc.
3. Axelgaard Manufacturing
4. B. Braun
5. BSN Medical
6. Cardinal Health
7. Coloplast
8. Convatec
9. DermaRite Industries
10. Hollister
11. Integra LifeSciences Holdings
12. Johnson & Johnson
13. Medline Industries
14. Molnlycke Health Care
15. Hartmann Group
16. Procyon Corp. (AMERX)
17. Smiths Group
18. Solventum Corporation
19. Winner Medical Co. Ltd
20. Zhende Medical Co. Ltd

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence of Chronic Wounds
  • 4.2.2 Shift from Gauze to Evidence-Based Dressings
  • 4.2.3 Innovation in Antimicrobial & Stimuli-Responsive Hydrogels
  • 4.2.4 Growing Surgical & Burn Cases Worldwide
  • 4.2.5 Outpatient-care Payment Reforms Favoring Low-Nurse-Time Dressings
  • 4.2.6 Sensor-Integrated Smart Hydrogels Enabling Tele-Wound Care
• 4.3 Market Restraints
  • 4.3.1 High Unit & Manufacturing Cost Versus Conventional Dressings
  • 4.3.2 Limited Absorption for Heavy-Exudate Wounds
  • 4.3.3 Supply-Chain Volatility for Specialty Polymers
  • 4.3.4 Extra Regulatory Hurdles for Drug-Device Combination Hydrogels
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Amorphous Hydrogel Dressings
  • 5.1.2 Impregnated Hydrogel Dressings
  • 5.1.3 Sheet Hydrogel Dressings
• 5.2 By Raw Material
  • 5.2.1 Synthetic Hydrogels
  • 5.2.2 Natural Hydrogels
  • 5.2.3 Semi-synthetic / Hybrid Hydrogels
• 5.3 By Application
  • 5.3.1 Chronic Wounds
    • 5.3.1.1 Diabetic Foot Ulcers
    • 5.3.1.2 Pressure Ulcers
    • 5.3.1.3 Venous Leg Ulcers
  • 5.3.2 Acute Wounds
    • 5.3.2.1 Burns
    • 5.3.2.2 Surgical & Traumatic Wounds
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Home Healthcare
  • 5.4.3 Ambulatory Surgical Centers
  • 5.4.4 Other End Users
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Advanced Medical Solutions Group
  • 6.3.2 Alliqua BioMedical / NEXGEL Inc.
  • 6.3.3 Axelgaard Manufacturing
  • 6.3.4 B. Braun Melsungen AG
  • 6.3.5 BSN Medical (Essity)
  • 6.3.6 Cardinal Health Inc.
  • 6.3.7 Coloplast A/S
  • 6.3.8 ConvaTec Group PLC
  • 6.3.9 DermaRite Industries LLC
  • 6.3.10 Hollister Incorporated
  • 6.3.11 Integra LifeSciences Holdings
  • 6.3.12 Johnson & Johnson (Ethicon)
  • 6.3.13 Medline Industries, Inc.
  • 6.3.14 Molnlycke Health Care AB
  • 6.3.15 Paul Hartmann AG
  • 6.3.16 Procyon Corp. (AMERX)
  • 6.3.17 Smith & Nephew plc
  • 6.3.18 Solventum Corporation
  • 6.3.19 Winner Medical Co. Ltd
  • 6.3.20 Zhende Medical Co. Ltd

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment